Ligand Pharmaceuticals | LGND - Current Liabilities


Ligand Pharmaceuticals reported $30.54M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Amgen USD 21.79B 1.32B Sep/2025
Arrowhead Research USD 195.49M 957K Sep/2025
Baxter International USD 3.78B 836M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Gilead Sciences USD 12.3B 1.11B Sep/2025
GlaxoSmithKline GBP 21.33B 956M Sep/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
Insmed USD 417.21M 105.53M Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Ligand Pharmaceuticals USD 30.54M 34.2M Sep/2025
MacroGenics USD 44.47M 5.47M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Pacira USD 107.08M 206.09M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Veracyte USD 72.15M 4.28M Sep/2025